grace capital Decreases Stake in Nevro Corp (NVRO)

Share on StockTwits

grace capital lowered its position in Nevro Corp (NYSE:NVRO) by 58.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,263 shares of the medical equipment provider’s stock after selling 7,514 shares during the period. grace capital’s holdings in Nevro were worth $420,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in NVRO. SG Americas Securities LLC purchased a new stake in shares of Nevro in the 1st quarter worth approximately $208,000. American Century Companies Inc. grew its stake in shares of Nevro by 24.5% in the 1st quarter. American Century Companies Inc. now owns 100,672 shares of the medical equipment provider’s stock worth $8,725,000 after buying an additional 19,818 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Nevro by 2,245.0% in the 1st quarter. Victory Capital Management Inc. now owns 2,345 shares of the medical equipment provider’s stock worth $203,000 after buying an additional 2,245 shares during the last quarter. Prudential Financial Inc. purchased a new stake in shares of Nevro in the 1st quarter worth approximately $252,000. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Nevro by 0.9% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 299,078 shares of the medical equipment provider’s stock worth $25,921,000 after buying an additional 2,671 shares during the last quarter.

Shares of Nevro stock opened at $61.38 on Friday. Nevro Corp has a one year low of $35.41 and a one year high of $94.34. The firm has a market capitalization of $1.88 billion, a P/E ratio of -49.10 and a beta of -0.71. The company has a current ratio of 8.06, a quick ratio of 6.29 and a debt-to-equity ratio of 0.61.

Nevro (NYSE:NVRO) last announced its earnings results on Thursday, August 2nd. The medical equipment provider reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.04). Nevro had a negative return on equity of 15.84% and a negative net margin of 10.68%. The company had revenue of $96.10 million during the quarter, compared to the consensus estimate of $96.10 million. During the same period in the prior year, the business posted ($0.40) earnings per share. Nevro’s revenue for the quarter was up 23.2% compared to the same quarter last year. analysts forecast that Nevro Corp will post -1.42 earnings per share for the current year.

Several analysts recently weighed in on the company. ValuEngine downgraded Nevro from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 14th. Morgan Stanley downgraded Nevro from an “overweight” rating to an “equal weight” rating and set a $95.00 target price on the stock. in a research note on Monday, July 2nd. Wells Fargo & Co cut their target price on Nevro from $84.00 to $62.00 and set a “market perform” rating on the stock in a research note on Tuesday, July 17th. Zacks Investment Research downgraded Nevro from a “hold” rating to a “sell” rating in a research note on Thursday, September 6th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Nevro in a research note on Wednesday, July 11th. Three analysts have rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $81.89.

Nevro Company Profile

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

See Also: Intrinsic Value

Institutional Ownership by Quarter for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Crystal Clear  One Day Volume Hits $34.00
Crystal Clear One Day Volume Hits $34.00
Denarius Market Capitalization Achieves $820,243.00
Denarius Market Capitalization Achieves $820,243.00
Analysts Set Universal Electronics Inc  Target Price at $43.00
Analysts Set Universal Electronics Inc Target Price at $43.00
Bridgewater Bancshares Inc  Given Consensus Recommendation of “Strong Buy” by Brokerages
Bridgewater Bancshares Inc Given Consensus Recommendation of “Strong Buy” by Brokerages
Allegheny Technologies Incorporated  VP Karl D. Schwartz Sells 1,000 Shares
Allegheny Technologies Incorporated VP Karl D. Schwartz Sells 1,000 Shares
Square  Stock Rating Reaffirmed by Stifel Nicolaus
Square Stock Rating Reaffirmed by Stifel Nicolaus


Leave a Reply

© 2006-2018 Ticker Report. Google+.